MariMed (OTCMKTS:MRMD – Get Rating) is one of 49 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare MariMed to related companies based on the strength of its profitability, institutional ownership, risk, analyst recommendations, dividends, valuation and earnings.
Earnings and Valuation
This table compares MariMed and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MariMed||$121.46 million||$7.22 million||30.77|
|MariMed Competitors||$238.87 million||-$88.85 million||-7.38|
This table compares MariMed and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for MariMed and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
MariMed currently has a consensus target price of $2.25, indicating a potential upside of 265.85%. As a group, “Medicinals & botanicals” companies have a potential upside of 123.32%. Given MariMed’s stronger consensus rating and higher probable upside, equities research analysts clearly believe MariMed is more favorable than its competitors.
Risk & Volatility
MariMed has a beta of 3.27, meaning that its stock price is 227% more volatile than the S&P 500. Comparatively, MariMed’s competitors have a beta of 1.49, meaning that their average stock price is 49% more volatile than the S&P 500.
Institutional and Insider Ownership
0.3% of MariMed shares are held by institutional investors. Comparatively, 16.3% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 20.0% of MariMed shares are held by insiders. Comparatively, 26.3% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
MariMed beats its competitors on 9 of the 13 factors compared.
About MariMed (Get Rating)
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand. It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.